首页> 美国卫生研究院文献>Nuclear Medicine and Molecular Imaging >Intratumoral Metabolic Heterogeneity for Prediction of Disease Progression After Concurrent Chemoradiotherapy in Patients with Inoperable Stage III Non-Small-Cell Lung Cancer

【2h】

Intratumoral Metabolic Heterogeneity for Prediction of Disease Progression After Concurrent Chemoradiotherapy in Patients with Inoperable Stage III Non-Small-Cell Lung Cancer

机译：肿瘤内代谢异质性用于无法手术的III期非小细胞肺癌患者同时放化疗后疾病进展的预测

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeWe evaluated the value of variable ¹⁸F-FDG PET/CT parameters for the prediction of disease progression after concurrent chemoradiotherapy (CCRT) in patients with inoperable stage III non-small-cell lung cancer (NSCLC).

机译：目的我们评估了可变的^{18 F-FDG PET / CT参数在无法手术的III期非小细胞肺癌（NSCLC）患者同时进行放化疗后的疾病进展预测中的价值。}

著录项

期刊名称 Nuclear Medicine and Molecular Imaging
作者
Sae-Ryung Kang; Ho-Chun Song; Byung Hyun Byun; Jong-Ryool Oh; Hyeon-Sik Kim; Sun-Pyo Hong; Seong Young Kwon; Ari Chong; Jahae Kim; Sang-Geon Cho; Hee Jeong Park; Young-Chul Kim; Sung-Ja Ahn; Jung-Joon Min; Hee-Seung Bom;
展开▼
作者单位

展开▼
年(卷),期 2014(48),1
年度 2014
页码 16–25
总页数 10
原文格式 PDF
正文语种
中图分类放射医学;影像诊断学;
关键词
Non-small-cell lung cancer Intratumoral heterogeneity Prognosis F-18 FDG PET;

机译：非小细胞肺癌;肿瘤内异质性;预后;F-18 FDG PET;

相似文献

外文文献
中文文献
专利

1. Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer. [J] . Lee DH, Han JY, Cho KH, International Journal of Radiation Oncology, Biology, Physics . 2005,第4期

机译：对于无法手术的III期非小细胞肺癌患者，吉西他滨和长春瑞滨诱导化疗联合口服依托泊苷和顺铂同步放化疗的II期研究。
2. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE) [J] . Eberhardt Wilfried Ernst Erich, Poettgen Christoph, Gauler Thomas Christoph, Journal of Clinical Oncology . 2015,第35期

机译：Ⅲ期外科手术与明确的同期放化疗联合治疗对可切除的ⅢA期（N2）和部分ⅢB期非小细胞肺癌患者的诱导化疗和同期放化疗（ESPATUE）
3. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. [J] . Kelly K, Chansky K, Gaspar LE, Journal of Clinical Oncology . 2008,第15期

机译：在无法手术的III期非小细胞肺癌中同时进行放化疗和多西他赛合并后维持吉非替尼或安慰剂的III期试验：SWOG S0023。
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. The effectiveness of chemoradiation for stage III non-small-cell lung cancer patients at the Kingston Regional Cancer Center (Ontario). [D] . Sinclair, Suzanne Marie. 2003

机译：金斯敦地区癌症中心（安大略省）对III期非小细胞肺癌患者进行化学放射治疗的有效性。
6. GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy [O] . Qing Zhou, Ming Chen, Gang Wu, 2020

机译：Gemstone-301：CS1001的III期临床试验作为局部晚期/不可切除（第III阶段）非小细胞肺癌（NSCLC）在先前同时/顺序化学疗法后没有疾病进展的患者的固结治疗
7. Intratumoral Metabolic Heterogeneity for Prediction of Disease Progression After Concurrent Chemoradiotherapy in Patients with Inoperable Stage III Non-Small-Cell Lung Cancer [O] . Sae-Ryung Kang, Ho-Chun Song, Byung Hyun Byun, 2013

机译：III阶段III阶段非小细胞肺癌患者同时化疗后疾病进展预测的肿瘤危险性代谢异质性

Intratumoral Metabolic Heterogeneity for Prediction of Disease Progression After Concurrent Chemoradiotherapy in Patients with Inoperable Stage III Non-Small-Cell Lung Cancer

摘要

著录项

相似文献

相关主题

期刊订阅